|
|
Post by morfu on Aug 5, 2020 16:57:03 GMT -5
I18 II18 III18 IV18 I19 II19 III19 IV19 I20 II20
Total revenues 3.4 3.8 4.4 16.0 17.5 15.0 14.6 16.0 16.2 15.1
of which
Afrezza net 3.4 3.8 4.4 5.7 5.0 6.1 6.4 7.8 8 7.0
collaboration 10.3 12.4 8.9 8.2 8.2 8.2 8.1
liane´s table 6.5 8.4 10 11.5 12.2 13.2 13.3 17.2 17.1 17.4
Anet over table .52 .45 .44 .50 .45 .46 .48 0.45 0.47 0.41
Afrezza gross profit -0.6* -1.3 0.7 1.1 1.7 2.1 3.1 3.8 3.3
R&D expenses -2.6 -3.0 2.0 -1.1 -1.7 -1.6 -1.6 -2.0 -1.8 -1.5
SG&A -15.4 -21.7 -19.4 -18.0 -27.7 -16.6 -16.7 -15.7 -14.4 -13.7
Interest expense -1.8 -1.7 -1.0 -0.6 -0.6 -0.6 -4.1 -2.3 -1 -2.7
net loss -30.4 -22.7 -24.2 -9.7 -14.9 -12.4 -10.4 -14.3 -9.3 10.7
Cash 27.2 53.1 11.0 71.7 59.8 38.2 50.4 50.2 38.9 63.5
|
|
|
|
Post by mytakeonit on Aug 5, 2020 17:01:21 GMT -5
Sounded good to me ... and if AH prices hold for tomorrow ... guess I get to buy more cheap shares. All I know is that the last 3 days puts my shares up 30 cents. That's equates to a Lamborghini for my daughter and a scooter for crayon boy.
But, that's mytakeonit
|
|
|
|
Post by agedhippie on Aug 5, 2020 17:11:47 GMT -5
Dilution always the solution. Minimal dilution, especially if the shares were sold during the run-up just prior to the warrant expiration. Better terms than a placement or Midcap. The ATM shares sold for an average of $1.64. |
|
|
|
Post by sportsrancho on Aug 5, 2020 17:28:11 GMT -5
So we didn’t need money huh..
matt do you think they will raise more, or will this hold us until the EOY..5 months give or take? I’m thinking we hear the same excuse about them being worried about the market.
|
|
|
|
Post by mytakeonit on Aug 5, 2020 18:09:51 GMT -5
I believe that the conference call was very straight forward and MNKD won't have any problems going forward. Let's see what the shareholder's think tomorrow. Volume went up to 5M+ ... which is a better area but still light.
But, that's mytakeonit
|
|
|
|
Post by morfu on Aug 5, 2020 20:36:21 GMT -5
I18 II18 III18 IV18 I19 II19 III19 IV19 I20 II20 Total revenues 3.4 3.8 4.4 16.0 17.5 15.0 14.6 16.0 16.2 15.1 of which Afrezza net 3.4 3.8 4.4 5.7 5.0 6.1 6.4 7.8 8 7.0 collaboration 10.3 12.4 8.9 8.2 8.2 8.2 8.1 liane´s table 6.5 8.4 10 11.5 12.2 13.2 13.3 17.2 17.1 17.4 Anet over table .52 .45 .44 .50 .45 .46 .48 0.45 0.47 0.41 Afrezza gross profit -0.6* -1.3 0.7 1.1 1.7 2.1 3.1 3.8 3.3 R&D expenses -2.6 -3.0 2.0 -1.1 -1.7 -1.6 -1.6 -2.0 -1.8 -1.5 SG&A -15.4 -21.7 -19.4 -18.0 -27.7 -16.6 -16.7 -15.7 -14.4 -13.7 Interest expense -1.8 -1.7 -1.0 -0.6 -0.6 -0.6 -4.1 -2.3 -1 -2.7 net loss -30.4 -22.7 -24.2 -9.7 -14.9 -12.4 -10.4 -14.3 -9.3 10.7 Cash 27.2 53.1 11.0 71.7 59.8 38.2 50.4 50.2 38.9 63.5 of course we had a net loss in this quarter so it should be -10.7 I am curious if we see that jump in net profit again at the end of this quarter.. if so we would have almost doubled this number in the last two years and another doubling over the next 5years would get us close to green.. from adult Afrezza sales in USA alone.. I kinda like these numbers!
|
|
|
|
Post by uvula on Aug 5, 2020 20:49:55 GMT -5
I guess the absence of bad news is sort of the same as good news, right?
|
|
|
|
Post by brotherm1 on Aug 6, 2020 8:20:13 GMT -5
They started the year with $50M
Ended Q2 6 mos later with $63M
From the $63M, take off $41.2M (from receipt of a $12.5 million United Therapeutics milestone payment, $12.2 million of net proceeds received from the at-the-market offering, $11.6 million received from warrant exercises and the origination of a Paycheck Protection Program loan for $4.9 million)= $21.8M they would have ended Q2 without the parenthesized)
They thus essentially burned $50M-$21.8M = $28.2M in six months ending June 30, or an avg. of $4.7M per month if I calculated correctly?
$63M, less $15M reserve, plus $12.5M from UTHR hopefully in December = $60.5M which at $4.7M burn per month could give them 12 mos cash from June 30
|
|
|
|
Post by mango on Aug 6, 2020 8:33:49 GMT -5
TreT FDA filing Q4
“finance, HR, moving fast to get secure the PPP loan, which definitely preserve jobs. Our employees are working under extremely difficult conditions maintained Afrezza production to keep TrepT on the right track and making clinical supplies there, as well as getting ready for the FDA filing later this year.”
—Michael Castagna EC 8/5/20
TreT FDA filing still on schedule
“And COVID-19 whilst delayed the Breeze study slightly, we don't expect any submission impact to the FDA on our timeline or additional trials we have to do to commit – to now and the end of the year. They were not on the critical path and they don't look like to be in the critical path as we open up the markets again.”
—Michael Castagna EC 8/5/20
Future Potential COVID-19 Inhaled Vaccine
“I'm hopeful as the vaccine comes available that we could be one of the partners to make an inhalable vaccine, like we've seen with the flu.”
—Michael Castagna EC 8/5/20
|
|
|
|
Post by matt on Aug 6, 2020 8:42:26 GMT -5
So we didn’t need money huh.. matt do you think they will raise more, or will this hold us until the EOY..5 months give or take? I’m thinking we hear the same excuse about them being worried about the market. Sorry, my crystal ball is in the shop for its annual service so I am unable to answer that question. However, consider that the cash flow from operations through six months was $-14.9 million and that the number included $16.4 million in collaboration payments from UTHR. In other words, but for the UTHR payments cash flow from operations for six months would have been $-31.3 million. If that loss rate continues going forward, then the cash balance of $63.3 million should suffice until year end which leaves the balance at around $30 million at year end of which $15 million is required to satisfy a MidCap covenant. In other words the company will be down to around one quarter of cash flow by December net of the MidCap covenant. However, it is never as simple as this and a few events could change that answer. If UTHR makes its fourth and final milestone payment, the cash can last a bit longer. Are there other UTHR-type deals in the works? Those could extend the runway significantly. If the government agrees to convert the PPP loan to a permanently-forgiven subsidy that will likewise help, but if the government decides that MNKD had adequate access to the capital markets and didn't really qualify for the PPP then the loan will come due sooner. Commercial sales of Afrezza are unlikely to be a material contributor of cash in the next few quarters. Given the overall economic environment management might simply decide that they need more of a cash cushion due to the reduced ability to forecast the future, and that would argue for more balance sheet cash. The number one rule in biotech is to raise money when you can and not when you need it. If the financial markets remain cooperative, I cannot fault any development stage company for raising more money. |
|
|
|
Post by agedhippie on Aug 6, 2020 8:42:37 GMT -5
... Future Potential COVID-19 Inhaled Vaccine
“I'm hopeful as the vaccine comes available that we could be one of the partners to make an inhalable vaccine, like we've seen with the flu.”—Michael Castagna EC 8/5/20 That's really interesting about the flu vaccine. Does anyone know anything about this? |
|
|
|
Post by peppy on Aug 6, 2020 8:51:15 GMT -5
... Future Potential COVID-19 Inhaled Vaccine
“I'm hopeful as the vaccine comes available that we could be one of the partners to make an inhalable vaccine, like we've seen with the flu.”—Michael Castagna EC 8/5/20 That's really interesting about the flu vaccine. Does anyone know anything about this? "All nasal spray influenza vaccines for the 2019-2020 season will contain four influenza viruses: an influenza A (H1N1) virus, an influenza A (H3N2) virus and two influenza B viruses." |
|
|
|
Post by uvula on Aug 6, 2020 8:56:18 GMT -5
... Future Potential COVID-19 Inhaled Vaccine
“I'm hopeful as the vaccine comes available that we could be one of the partners to make an inhalable vaccine, like we've seen with the flu.”—Michael Castagna EC 8/5/20 That's really interesting about the flu vaccine. Does anyone know anything about this? It exists but has nothing to do with MNKD. www.flumistquadrivalent.com/Mike chose his words carefully so he could not be accused of claiming that there was a connection between mnkd and an inhalable flu vaccine. |
|
|
|
Post by alethea on Aug 6, 2020 8:57:29 GMT -5
Nonetheless I expect/predict that the hedgies and/or shorts that routinely control and manipulate the stock price will open tomorrow with a strong downward push to scare folks and create the perception that the call was not good. DON'T BE FOOLED. Things are looking up. Here is the predicted head-fake by the shorts. They ran it up and closed yesterday at 1.86 so that they could CRASH it down today and after hours yesterday. Make it look terrible as it is off today by 14 or 15% from yesterday's inflated close. (inflated by them). I'm finding this rather amusing. Yesterday's call was very good. $63 in cash, no need for dilution for at least 6 months. Today's action is a deceptive joke. These crooks have controlled MNKD stock for years and have made massive money. They're starting to lose their grip. To the extent I can, I'm adding more today. |
|
|
|
Post by agedhippie on Aug 6, 2020 8:59:34 GMT -5
That's really interesting about the flu vaccine. Does anyone know anything about this? "All nasal spray influenza vaccines for the 2019-2020 season will contain four influenza viruses: an influenza A (H1N1) virus, an influenza A (H3N2) virus and two influenza B viruses." Ah. I thought there was a Technosphere partnership to deliver it and was getting excited because that's a huge market, especially amongst diabetics (try getting out of your endo's office with a flu shot...) It would have been a nice introduction to Technosphere, and by extension Afrezza. |
|
